2019
DOI: 10.3390/ijms20163850
|View full text |Cite
|
Sign up to set email alerts
|

F-Spondin Is the Signal by Which 2-Methoxyestradiol Induces Apoptosis in the Endometrial Cancer Cell Line Ishikawa

Abstract: The metabolite 2-methoxyestradiol (2ME) is an endogenous estrogen metabolite with potential therapeutic properties in reproductive cancers. However, the molecular mechanisms by which 2ME exerts its anticancer activity are not well elucidated. The purpose of this study was to determine the molecular signals associated with the apoptotic effects of 2ME in a human endometrial cancer cell line. Ishikawa cells were treated with non-apoptotic (0.1 µM) or apoptotic concentrations (5 µM) of 2ME, and 12 hours later mRN… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 8 publications
(12 citation statements)
references
References 30 publications
0
12
0
Order By: Relevance
“…However, very few studies have addressed the possible mechanisms of SNX6 in modulating cancerous/neoplastic diseases. Rincón‐Rodriguez et al (2019) have demonstrated that SNX6 is a target gene of the metabolite 2‐methoxyestradiol (2ME) that is an endogenous estrogen metabolite with potential therapeutic properties in reproductive cancers. They have further found that SNX6 is responding to 2ME both in apoptotic and nonapoptotic concentrations, suggesting the suppressor role of SNX6 in endometrial cancer (Rincon‐Rodriguez et al, 2019).…”
Section: Role Of Snxs In Cancerous/neoplastic Diseasesmentioning
confidence: 99%
“…However, very few studies have addressed the possible mechanisms of SNX6 in modulating cancerous/neoplastic diseases. Rincón‐Rodriguez et al (2019) have demonstrated that SNX6 is a target gene of the metabolite 2‐methoxyestradiol (2ME) that is an endogenous estrogen metabolite with potential therapeutic properties in reproductive cancers. They have further found that SNX6 is responding to 2ME both in apoptotic and nonapoptotic concentrations, suggesting the suppressor role of SNX6 in endometrial cancer (Rincon‐Rodriguez et al, 2019).…”
Section: Role Of Snxs In Cancerous/neoplastic Diseasesmentioning
confidence: 99%
“…While SPON1 expression is found in malignancies including ovarian cancer [ 44 ], the effect of SPON1 depends on the cancer type. In osteosarcoma cells, SPON1 promotes cell migration and invasion [ 45 ], whereas SPON1 exhibits an antioncogenic roles in some tumors: SPON1 expression is negatively correlated with survival in bladder cancer [ 46 ], SPON1 mediates the apoptotic effect of anticancer reagent in uterine endometrial cancer cells [ 47 ], and SPON1 suppression leads to proliferation, migration, and invasion in hepatocellular carcinoma [ 48 ]. In the putative fusion protein based on the SPON1-TRIM29 transcript, it contains 115 amino acids of SPON1 N-terminal signal sequence, whereas it lacks the rest of a large region containing reeler, spondin N, and thrombospondin type1 domains, which are conserved in spondin-like extracellular matrix proteins [ 49 ].…”
Section: Discussionmentioning
confidence: 99%
“…in PI channel. 2-methoxiestradiol (2ME) 5 µM was used as positive control 26 , 27 and untreated cells were used as control. The percentages for each cell cycle stage were analyzed by the ModFit LT program (v5.0.9, Verity Software House), and the subG1 population was excluded from the histogram because the purpose of this assay was the analysis of cell cycle.…”
Section: Methodsmentioning
confidence: 99%
“…to analyze viable (double negative), early apoptotic (Annexin V positive), late apoptotic (Annexin V positive, PI positive), and necrotic (PI positive) populations in BD Accuri C6 software (version 1.0.264.21, Accuri ® cytometers, Inc.). As positive control we used 2ME 5 µM 26 , 27 and untreated cells were used as control.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation